QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NASDAQ:TRVI

Trevi Therapeutics - TRVI Stock Forecast, Price & News

$3.78
-0.33 (-8.03%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.78
▼
$4.10
50-Day Range
$1.94
▼
$4.28
52-Week Range
$0.46
▼
$4.68
Volume
180,449 shs
Average Volume
1.11 million shs
Market Capitalization
$146.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Trevi Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
182.2% Upside
$10.67 Price Target
Short Interest
Healthy
1.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.23mentions of Trevi Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1.57 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.81) to ($0.77) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

87th out of 1,125 stocks

Pharmaceutical Preparations Industry

29th out of 554 stocks

See Top Rated MarketRank™ Stocks Here
TRVI stock logo

About Trevi Therapeutics (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics Stock Down 3.7 %

Shares of TRVI opened at $4.11 on Monday. The business's 50 day moving average is $3.10 and its 200 day moving average is $2.29. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.67. Trevi Therapeutics has a 12-month low of $0.46 and a 12-month high of $4.68. The company has a market capitalization of $159.00 million, a PE ratio of -4.11 and a beta of 0.21.

Trevi Therapeutics (NASDAQ:TRVI - Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.07. During the same quarter in the prior year, the firm posted ($0.43) EPS. Research analysts expect that Trevi Therapeutics will post -0.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Needham & Company LLC raised their target price on shares of Trevi Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, June 29th. Oppenheimer lifted their target price on shares of Trevi Therapeutics to $12.00 in a research note on Monday, July 4th.

Insider Buying and Selling

In other Trevi Therapeutics news, major shareholder Tpg Gp A, Llc sold 46,128 shares of Trevi Therapeutics stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $2.74, for a total value of $126,390.72. Following the sale, the insider now directly owns 4,754,721 shares in the company, valued at approximately $13,027,935.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders sold 546,128 shares of company stock worth $1,572,283. 39.52% of the stock is owned by insiders.

Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

August 11, 2022 | finance.yahoo.com
Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
August 8, 2022 | msn.com
Gloria Trevi On the Highs and Lows of Her 40-Year Career — And What Has Remained Consistent In Her Music
August 4, 2022 | finance.yahoo.com
Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
July 19, 2022 | finance.yahoo.com
Is Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) Shareholder Ownership Skewed Towards Insiders?
July 14, 2022 | finance.yahoo.com
Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics
July 6, 2022 | uk.finance.yahoo.com
Which way is the Trevi Therapeutics share price trending?
July 3, 2022 | americanbankingnews.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update
June 30, 2022 | finance.yahoo.com
Why Did Needham Lift Price Target For Trevi?
June 30, 2022 | stocknews.com
Wall Street Predicts These 2 Sub-$5 Stocks Have More Than 200% Upside
June 29, 2022 | finance.yahoo.com
Why Trevi Therapeutics Shares Trading Higher Today?
June 29, 2022 | investorplace.com
Trevi Therapeutics (TRVI) Stock Spikes 20% on Positive Clinical Data
June 29, 2022 | investorplace.com
Trevi Therapeutics (TRVI) Spikes 20% on Positive Clinical Data
June 29, 2022 | seekingalpha.com
Trevi surges 29% as trial for pain therapy meets key goals in skin disorder
June 29, 2022 | finance.yahoo.com
Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis
June 29, 2022 | finance.yahoo.com
Trevi's stock gains 38% after announcing positive data for skin-disease drug
June 23, 2022 | finance.yahoo.com
These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer
June 7, 2022 | finance.yahoo.com
Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention
May 25, 2022 | seekingalpha.com
Trevi Therapeutics initiated at outperform at Oppenheimer on chronic cough candidate
May 13, 2022 | benzinga.com
Recap: Trevi Therapeutics Q1 Earnings
May 13, 2022 | finance.yahoo.com
Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update
May 5, 2022 | finance.yahoo.com
Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022
May 3, 2022 | finance.yahoo.com
Trevi Therapeutics to Present at Upcoming May Meetings
April 13, 2022 | finance.yahoo.com
Are You Looking for a Top Momentum Pick? Why Trevi Therapeutics, Inc. (TRVI) is a Great Choice
April 8, 2022 | investorplace.com
Why Is Trevi Therapeutics (TRVI) Stock On the Move Today?
April 7, 2022 | seekingalpha.com
Trevi Therapeutics stock slides on $55M private securities offering
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Company Calendar

Last Earnings
11/10/2021
Today
8/15/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVI
CUSIP
N/A
CIK
1563880
Web
www.trevitherapeutics.com
Phone
(203) 304-2499
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+182.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,940,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-125.34%
Return on Assets
-68.53%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
5.18
Quick Ratio
5.18

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.66 per share
Price / Book
5.73

Miscellaneous

Outstanding Shares
38,686,000
Free Float
25,868,000
Market Cap
$146.23 million
Optionable
Not Optionable
Beta
0.21

Key Executives

  • Ms. Jennifer L. Good (Age 57)
    Co-Founder, CEO, Pres & Director
    Comp: $731.41k
  • Dr. Thomas R. Sciascia (Age 69)
    Co-Founder & Chief Medical Officer
    Comp: $499.65k
  • Dr. William P. Forbes Pharm. D. (Age 60)
    Pharm.D., Chief Devel. Officer
    Comp: $596.74k
  • Ms. Lisa Delfini (Age 52)
    Chief Financial Officer
  • Mr. Christopher Galletta (Age 44)
    Controller & Chief Accounting Officer
  • Mr. Frank P. Muscolo (Age 65)
    Exec. Officer
  • Ms. Danine Summers (Age 64)
    VP of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TRVI Stock - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings or view top-rated stocks.

What is Trevi Therapeutics' stock price forecast for 2022?

3 brokers have issued 1-year price objectives for Trevi Therapeutics' stock. Their TRVI share price forecasts range from $10.00 to $12.00. On average, they predict the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 182.2% from the stock's current price.
View analysts price targets for TRVI or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2022?

Trevi Therapeutics' stock was trading at $0.7822 on January 1st, 2022. Since then, TRVI stock has increased by 383.3% and is now trading at $3.78.
View the best growth stocks for 2022 here.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our TRVI earnings forecast.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.01. During the same quarter last year, the firm posted ($0.41) earnings per share.

What other stocks do shareholders of Trevi Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Trevena (TRVN), Diffusion Pharmaceuticals (DFFN), Fulcrum Therapeutics (FULC), Genocea Biosciences (GNCA), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), AzurRx BioPharma (AZRX) and Chimerix (CMRX).

When did Trevi Therapeutics IPO?

(TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

What is Trevi Therapeutics' stock symbol?

Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI."

Who are Trevi Therapeutics' major shareholders?

Trevi Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include TPG GP A LLC (11.18%), MAI Capital Management (5.27%), Frazier Life Sciences Management L.P. (3.03%), Renaissance Technologies LLC (0.39%), WealthTrust Axiom LLC (0.24%) and FMR LLC (0.22%). Insiders that own company stock include Enterprise Associates 16 New, Paul Edward Walker and Tpg Gp A, Llc.
View institutional ownership trends.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevi Therapeutics' stock price today?

One share of TRVI stock can currently be purchased for approximately $3.78.

How much money does Trevi Therapeutics make?

Trevi Therapeutics (NASDAQ:TRVI) has a market capitalization of $146.23 million. The company earns $-33,940,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact Trevi Therapeutics?

Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is www.trevitherapeutics.com. The company can be reached via phone at (203) 304-2499 or via email at peter.vozzo@westwicke.com.

This page (NASDAQ:TRVI) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.